Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 254

1.

Unexpected adverse effect of metyrapone: a case report.

Rouland A, Nguyen A, Fourmont C, Lapray M, Vergès B, Petit JM, Bouillet B.

Clin Endocrinol (Oxf). 2018 Apr 19. doi: 10.1111/cen.13718. [Epub ahead of print]

PMID:
29672894
2.

Detection of glucose metabolism disorders in coronary patients enrolled in cardiac rehabilitation: Is glycated haemoglobin useful? Data from the prospective REHABDIAB study.

Tatulashvili S, Patois-Vergès B, Nguyen A, Blonde MC, Vergès B.

Eur J Prev Cardiol. 2018 Mar;25(5):464-471. doi: 10.1177/2047487317754011. Epub 2018 Jan 26.

PMID:
29370710
3.

[Interferences of biotin therapy on immunoassays: It is time for a long-term solution!]

Denimal D, Nguyen A, Fromont A, Moreau T, Vergès B, Duvillard L.

Presse Med. 2018 Jan;47(1):95-97. doi: 10.1016/j.lpm.2017.09.027. Epub 2017 Dec 20. French. No abstract available.

PMID:
29275027
4.

European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) clinical practice recommendations for the management of non-alcoholic fatty liver disease: evaluation of their application in people with Type 2 diabetes.

Sberna AL, Bouillet B, Rouland A, Brindisi MC, Nguyen A, Mouillot T, Duvillard L, Denimal D, Loffroy R, Vergès B, Hillon P, Petit JM.

Diabet Med. 2018 Mar;35(3):368-375. doi: 10.1111/dme.13565. Epub 2018 Jan 10.

PMID:
29247558
5.

Liver Fat Content in People with Pituitary Diseases: Influence of Serum IGF1 Levels.

Nguyen A, Ricolfi F, Lemogne B, Aho S, Lemaire S, Bouillet B, Duvillard L, Denimal D, Fourmont C, Loffroy R, Cercueil JP, Verges B, Petit JM.

Horm Metab Res. 2018 Apr;50(4):303-307. doi: 10.1055/s-0043-120673. Epub 2017 Oct 24.

PMID:
29065431
6.

Application of the new eLIFT test for the non-invasive diagnosis of advanced liver fibrosis in people with type 2 diabetes.

Petit JM, Bouillet B, Loffroy R, Rouland A, Hillon P, Verges B.

J Hepatol. 2018 Mar;68(3):603-604. doi: 10.1016/j.jhep.2017.08.036. Epub 2017 Oct 4. No abstract available.

PMID:
28987518
7.

Histologically Proven Bronchial Neuroendocrine Tumors in MEN1: A GTE 51-Case Cohort Study.

Lecomte P, Binquet C, Le Bras M, Tabarin A, Cardot-Bauters C, Borson-Chazot F, Lombard-Bohas C, Baudin E, Delemer B, Klein M, Vergès B, Aparicio T, Cosson E, Beckers A, Caron P, Chabre O, Chanson P, Du Boullay H, Guilhem I, Niccoli P, Rohmer V, Guigay J, Vulpoi C, Scoazec JY, Goudet P.

World J Surg. 2018 Jan;42(1):143-152. doi: 10.1007/s00268-017-4135-z.

PMID:
28785839
8.

Uptake in the pancreatic uncinate process on the 111In-octreotide scintigraphy: How to distinguish physiological from pathological uptake?

Ait Boudaoud A, Verges B, Petit JM, Tatulashvili S, Cochet A, Humbert O.

Nucl Med Commun. 2017 Sep;38(9):737-743. doi: 10.1097/MNM.0000000000000710.

PMID:
28704340
9.

High efficacy of screening for diabetes and prediabetes in cardiac rehabilitation after an acute coronary syndrome (ACS). The REHABDIAB study.

Vergès B, Patois-Vergès B, Goueslard K, Cottenet J, Nguyen A, Tatulashvili S, Blonde MC, Quantin C.

Diabetes Metab. 2017 Jun 29. pii: S1262-3636(17)30110-6. doi: 10.1016/j.diabet.2017.05.012. [Epub ahead of print] No abstract available.

PMID:
28669513
10.

Effects of anti-somatostatin agents on glucose metabolism.

Vergès B.

Diabetes Metab. 2017 Oct;43(5):411-415. doi: 10.1016/j.diabet.2017.05.003. Epub 2017 Jun 1. Review.

PMID:
28579289
11.

After the LEADER trial and SUSTAIN-6, how do we explain the cardiovascular benefits of some GLP-1 receptor agonists?

Vergès B, Charbonnel B.

Diabetes Metab. 2017 Apr;43 Suppl 1:2S3-2S12. doi: 10.1016/S1262-3636(17)30067-8.

PMID:
28431669
12.

GLP-1 receptor agonists in NAFLD.

Petit JM, Vergès B.

Diabetes Metab. 2017 Apr;43 Suppl 1:2S28-2S33. doi: 10.1016/S1262-3636(17)30070-8.

PMID:
28431668
13.

Impairment of the Ability of HDL From Patients With Metabolic Syndrome but Without Diabetes Mellitus to Activate eNOS: Correction by S1P Enrichment.

Denimal D, Monier S, Brindisi MC, Petit JM, Bouillet B, Nguyen A, Demizieux L, Simoneau I, Pais de Barros JP, Vergès B, Duvillard L.

Arterioscler Thromb Vasc Biol. 2017 May;37(5):804-811. doi: 10.1161/ATVBAHA.117.309287. Epub 2017 Mar 30.

PMID:
28360087
14.

Overactivation of the endocannabinoid system alters the antilipolytic action of insulin in mouse adipose tissue.

Muller T, Demizieux L, Troy-Fioramonti S, Gresti J, Pais de Barros JP, Berger H, Vergès B, Degrace P.

Am J Physiol Endocrinol Metab. 2017 Jul 1;313(1):E26-E36. doi: 10.1152/ajpendo.00374.2016. Epub 2017 Mar 21.

PMID:
28325733
15.

mTOR and Cardiovascular Diseases: Diabetes Mellitus.

Vergès B.

Transplantation. 2018 Feb;102(2S Suppl 1):S47-S49. doi: 10.1097/TP.0000000000001722.

PMID:
28263222
16.

Personal model-assisted identification of NAD+ and glutathione metabolism as intervention target in NAFLD.

Mardinoglu A, Bjornson E, Zhang C, Klevstig M, Söderlund S, Ståhlman M, Adiels M, Hakkarainen A, Lundbom N, Kilicarslan M, Hallström BM, Lundbom J, Vergès B, Barrett PH, Watts GF, Serlie MJ, Nielsen J, Uhlén M, Smith U, Marschall HU, Taskinen MR, Boren J.

Mol Syst Biol. 2017 Mar 2;13(3):916. doi: 10.15252/msb.20167422.

17.

Consensus statement on the management of dyslipidaemias in adults.

French Society of Endocrinology (SFE); Francophone Society of Diabetes (SFD); New French Society of Atherosclerosis (NSFA), Béliard S, Bonnet F, Bouhanick B, Bruckert E, Cariou B, Charrière S, Durlach V, Moulin P, Valéro R, Vergès B.

Ann Endocrinol (Paris). 2017 Feb;78(1):43-53. doi: 10.1016/j.ando.2016.11.001. Epub 2017 Jan 12. No abstract available.

PMID:
28089403
18.

Fatty acid dietary intake in the general French population: are the French Agency for Food, Environmental and Occupational Health & Safety (ANSES) national recommendations met?

Tressou J, Moulin P, Vergès B, Le Guillou C, Simon N, Pasteau S.

Br J Nutr. 2016 Dec;116(11):1966-1973. doi: 10.1017/S000711451600413X. Epub 2016 Dec 20.

PMID:
27993183
19.

Glycaemic control influences the relationship between plasma PCSK9 and LDL cholesterol in type 1 diabetes.

Laugier-Robiolle S, Vergès B, Le Bras M, Gand E, Bouillet B, Saulnier PJ, Le May C, Pichelin M, Maréchaud R, Petit JM, Hadjadj S, Cariou B.

Diabetes Obes Metab. 2017 Mar;19(3):448-451. doi: 10.1111/dom.12819. Epub 2016 Dec 8.

PMID:
27804190
20.

Adrenal lymphoma: presentation, management and prognosis.

Laurent C, Casasnovas O, Martin L, Chauchet A, Ghesquieres H, Aussedat G, Fornecker LM, Bologna S, Borot S, Laurent K, Bouillet B, Verges B, Petit JM.

QJM. 2017 Feb 1;110(2):103-109. doi: 10.1093/qjmed/hcw174.

PMID:
27795295
21.

[Management of hyperglycemic/diabetic patient during and in the immediate follow-up of an acute coronary syndrome].

Vergès B.

Presse Med. 2016 Oct;45(10):865-870. doi: 10.1016/j.lpm.2016.05.022. Epub 2016 Jun 30. French.

PMID:
27374266
22.

Effect of Liraglutide Therapy on Liver Fat Content in Patients With Inadequately Controlled Type 2 Diabetes: The Lira-NAFLD Study.

Petit JM, Cercueil JP, Loffroy R, Denimal D, Bouillet B, Fourmont C, Chevallier O, Duvillard L, Vergès B.

J Clin Endocrinol Metab. 2017 Feb 1;102(2):407-415. doi: 10.1210/jc.2016-2775.

PMID:
27732328
23.

Consensus statement on the management of dyslipidaemias in adults.

French Society of Endocrinology (SFE); Francophone Society of Diabetes (SFD); New French Society of Atherosclerosis (NSFA), Béliard S, Bonnet F, Bouhanick B, Bruckert E, Cariou B, Charrière S, Durlach V, Moulin P, Valéro R, Vergès B.

Diabetes Metab. 2016 Dec;42(6):398-408. doi: 10.1016/j.diabet.2016.07.033. Epub 2016 Sep 20. No abstract available.

PMID:
27659248
24.

Reasons for non-intensification of treatment in people with type 2 diabetes receiving oral monotherapy: Outcomes from the prospective DIAttitude study.

Balkau B, Halimi S, Blickle JF, Vergès B, Avignon A, Attali C, Chartier I, Amelineau E.

Ann Endocrinol (Paris). 2016 Dec;77(6):649-657. doi: 10.1016/j.ando.2016.03.001. Epub 2016 Sep 16.

PMID:
27646493
25.

Effects of Transcranial Magnetic Stimulation on the Hypothalamic-Pituitary Axis in Depression: Results of a Pilot Study.

Meille V, Verges B, Lalanne L, Jonval L, Duvillard L, Chavet-Gelinier JC, Bonin B, Trojak B.

J Neuropsychiatry Clin Neurosci. 2017 Winter;29(1):70-73. doi: 10.1176/appi.neuropsych.16010013. Epub 2016 Aug 19.

PMID:
27539376
26.

Type A personality is not associated with poor glycaemic control: Data from cross-sectional and longitudinal surveys of people with type 1 or type 2 diabetes.

Chauvet-Gélinier JC, Trojak B, Lemogne C, Louprou A, Bouillet B, Simoneau I, Chahraoui K, Petit JM, Consoli SM, Bonin B, Vergès B.

Diabetes Metab. 2017 Apr;43(2):176-179. doi: 10.1016/j.diabet.2016.06.006. Epub 2016 Aug 5. No abstract available.

PMID:
27502117
27.

Plasma apolipoprotein C1 concentration is associated with plasma triglyceride concentration, but not visceral fat, in patients with type 2 diabetes.

Bouillet B, Gautier T, Aho LS, Duvillard L, Petit JM, Lagrost L, Vergès B.

Diabetes Metab. 2016 Sep;42(4):263-6. doi: 10.1016/j.diabet.2016.01.003. Epub 2016 Feb 28.

PMID:
26934823
28.

ApoA-II HDL Catabolism and Its Relationships With the Kinetics of ApoA-I HDL and of VLDL1, in Abdominal Obesity.

Vergès B, Adiels M, Boren J, Barrett PH, Watts GF, Chan D, Duvillard L, Söderlund S, Matikainen N, Kahri J, Lundbom N, Lundbom J, Hakkarainen A, Aho S, Simoneau-Robin I, Taskinen MR.

J Clin Endocrinol Metab. 2016 Apr;101(4):1398-406. doi: 10.1210/jc.2015-3740. Epub 2016 Feb 2.

PMID:
26835543
29.

Liver fat content is negatively associated with atherosclerotic carotid plaque in type 2 diabetic patients.

Loffroy R, Terriat B, Jooste V, Robin I, Brindisi MC, Hillon P, Vergès B, Cercueil JP, Petit JM.

Quant Imaging Med Surg. 2015 Dec;5(6):792-8. doi: 10.3978/j.issn.2223-4292.2015.12.03.

30.

Major changes in the sphingophospholipidome of HDL in non-diabetic patients with metabolic syndrome.

Denimal D, Nguyen A, Pais de Barros JP, Bouillet B, Petit JM, Vergès B, Duvillard L.

Atherosclerosis. 2016 Mar;246:106-14. doi: 10.1016/j.atherosclerosis.2015.12.042. Epub 2016 Jan 2.

PMID:
26773402
31.

[TREATMENT OF TYPE 2 DIABETES IN PATIENTS WITH HISTORY OF CARDIOVASCULAR DISEASE].

Vergès B.

Rev Prat. 2015 Oct;65(8):1050-3. French.

PMID:
26749704
32.

Improvement of liver function tests by antidiabetic agents: The need for multidirectional analysis.

Vergès B, Petit JM, Bouillet B.

Diabetes Metab. 2016 Feb;42(1):1-3. doi: 10.1016/j.diabet.2015.11.001. Epub 2015 Dec 8. No abstract available.

PMID:
26677771
33.

mTOR inhibitors and diabetes.

Vergès B, Cariou B.

Diabetes Res Clin Pract. 2015 Nov;110(2):101-8. doi: 10.1016/j.diabres.2015.09.014. Epub 2015 Sep 21. Review.

PMID:
26421362
34.

Unraveling the intrafamilial correlations and heritability of tumor types in MEN1: a Groupe d'étude des Tumeurs Endocrines study.

Thevenon J, Bourredjem A, Faivre L, Cardot-Bauters C, Calender A, Le Bras M, Giraud S, Niccoli P, Odou MF, Borson-Chazot F, Barlier A, Lombard-Bohas C, Clauser E, Tabarin A, Pasmant E, Chabre O, Castermans E, Ruszniewski P, Bertherat J, Delemer B, Christin-Maitre S, Beckers A, Guilhem I, Rohmer V, Goichot B, Caron P, Baudin E, Chanson P, Groussin L, Du Boullay H, Weryha G, Lecomte P, Schillo F, Bihan H, Archambeaud F, Kerlan V, Bourcigaux N, Kuhn JM, Vergès B, Rodier M, Renard M, Sadoul JL, Binquet C, Goudet P.

Eur J Endocrinol. 2015 Dec;173(6):819-26. doi: 10.1530/EJE-15-0691. Epub 2015 Sep 21.

35.

Potential influence of Type A personality on plasma C-reactive protein levels in people with diabetes.

Chauvet-Gélinier JC, Trojak B, Lemogne C, Aho-Glélé LS, Brindisi MC, Bouillet B, Ponavoy E, Meille V, Simoneau I, Chahraoui K, Vaillant G, Petit JM, Consoli SM, Bonin B, Vergès B.

Diabetes Metab. 2016 Apr;42(2):88-95. doi: 10.1016/j.diabet.2015.08.001. Epub 2015 Sep 15.

PMID:
26385557
36.

Kinetic and Related Determinants of Plasma Triglyceride Concentration in Abdominal Obesity: Multicenter Tracer Kinetic Study.

Borén J, Watts GF, Adiels M, Söderlund S, Chan DC, Hakkarainen A, Lundbom N, Matikainen N, Kahri J, Vergès B, Barrett PH, Taskinen MR.

Arterioscler Thromb Vasc Biol. 2015 Oct;35(10):2218-24. doi: 10.1161/ATVBAHA.115.305614. Epub 2015 Aug 27. Erratum in: Arterioscler Thromb Vasc Biol. 2015 Nov;35(11):e57.

37.

Influence of glycemic control on gain in VO2 peak, in patients with type 2 diabetes enrolled in cardiac rehabilitation after an acute coronary syndrome. The prospective DARE study.

Vergès B, Patois-Vergès B, Iliou MC, Simoneau-Robin I, Bertrand JH, Feige JM, Douard H, Catargi B, Fischbach M; DARE Study group.

BMC Cardiovasc Disord. 2015 Jul 8;15:64. doi: 10.1186/s12872-015-0055-8.

38.

Significant abnormalities of the HDL phosphosphingolipidome in type 1 diabetes despite normal HDL cholesterol concentration.

Denimal D, Pais de Barros JP, Petit JM, Bouillet B, Vergès B, Duvillard L.

Atherosclerosis. 2015 Aug;241(2):752-60. doi: 10.1016/j.atherosclerosis.2015.06.040. Epub 2015 Jun 29.

PMID:
26142685
39.

Type 1 diabetes is not associated with an increased prevalence of hepatic steatosis.

Petit JM, Pedro L, Guiu B, Duvillard L, Bouillet B, Jooste V, Habchi M, Crevisy E, Fourmont C, Buffier P, Hillon P, Cercueil JP, Verges B.

Diabet Med. 2015 Dec;32(12):1648-51. doi: 10.1111/dme.12805. Epub 2015 May 30.

PMID:
25981893
40.

GCKR polymorphism influences liver fat content in patients with type 2 diabetes.

Petit JM, Masson D, Guiu B, Rollot F, Duvillard L, Bouillet B, Brindisi MC, Buffier P, Hillon P, Cercueil JP, Verges B.

Acta Diabetol. 2016 Apr;53(2):237-42. doi: 10.1007/s00592-015-0766-4. Epub 2015 May 16.

PMID:
25976242
41.

Pathophysiology of diabetic dyslipidaemia: where are we?

Vergès B.

Diabetologia. 2015 May;58(5):886-99. doi: 10.1007/s00125-015-3525-8. Epub 2015 Mar 1. Review.

42.

MEN1 disease occurring before 21 years old: a 160-patient cohort study from the Groupe d'étude des Tumeurs Endocrines.

Goudet P, Dalac A, Le Bras M, Cardot-Bauters C, Niccoli P, Lévy-Bohbot N, du Boullay H, Bertagna X, Ruszniewski P, Borson-Chazot F, Vergès B, Sadoul JL, Ménégaux F, Tabarin A, Kühn JM, d'Anella P, Chabre O, Christin-Maitre S, Cadiot G, Binquet C, Delemer B.

J Clin Endocrinol Metab. 2015 Apr;100(4):1568-77. doi: 10.1210/jc.2014-3659. Epub 2015 Jan 16.

PMID:
25594862
43.

Adverse effects and safety of SGLT-2 inhibitors.

Halimi S, Vergès B.

Diabetes Metab. 2014 Dec;40(6 Suppl 1):S28-34. doi: 10.1016/S1262-3636(14)72693-X. Review.

PMID:
25554069
44.

Potential risks associated with increased plasma plant-sterol levels.

Vergès B, Fumeron F.

Diabetes Metab. 2015 Feb;41(1):76-81. doi: 10.1016/j.diabet.2014.11.003. Epub 2014 Dec 9.

PMID:
25497968
45.

Acute activation of cannabinoid receptors by anandamide reduces gastrointestinal motility and improves postprandial glycemia in mice.

Troy-Fioramonti S, Demizieux L, Gresti J, Muller T, Vergès B, Degrace P.

Diabetes. 2015 Mar;64(3):808-18. doi: 10.2337/db14-0721. Epub 2014 Oct 3.

46.

Glycated albumin with loss of fatty acid binding capacity contributes to enhanced arachidonate oxygenation and platelet hyperactivity: relevance in patients with type 2 diabetes.

Blache D, Bourdon E, Salloignon P, Lucchi G, Ducoroy P, Petit JM, Verges B, Lagrost L.

Diabetes. 2015 Mar;64(3):960-72. doi: 10.2337/db14-0879. Epub 2014 Aug 25.

47.

No improvement of high-density lipoprotein (HDL) vasorelaxant effect despite increase in HDL cholesterol concentration in type 2 diabetic patients treated with glitazones.

Perségol L, Duvillard L, Monier S, Brindisi MC, Bouillet B, Petit JM, Vergès B.

J Clin Endocrinol Metab. 2014 Oct;99(10):E2015-9. doi: 10.1210/jc.2014-2078. Epub 2014 Aug 19.

PMID:
25137425
48.

Interrelationships between the kinetics of VLDL subspecies and HDL catabolism in abdominal obesity: a multicenter tracer kinetic study.

Vergès B, Adiels M, Boren J, Barrett PH, Watts GF, Chan D, Duvillard L, Söderlund S, Matikainen N, Kahri J, Robin I, Taskinen MR.

J Clin Endocrinol Metab. 2014 Nov;99(11):4281-90. doi: 10.1210/jc.2014-2365. Epub 2014 Jul 31.

PMID:
25077901
49.

Oxidation-induced loss of the ability of HDL to counteract the inhibitory effect of oxidized LDL on vasorelaxation.

Perségol L, Brindisi MC, Rageot D, Pais de Barros JP, Monier S, Vergès B, Duvillard L.

Heart Vessels. 2015 Nov;30(6):845-9. doi: 10.1007/s00380-014-0543-2. Epub 2014 Jul 17.

PMID:
25031153
50.

Characteristics of diabetic patients and diabetes care in cardiac rehabilitation.

Beacco M, Vergès-Patois B, Blonde MC, Crevisy E, Habchi M, Bouillet B, Buffier P, Petit JM, Vergès B.

Arch Cardiovasc Dis. 2014 Jun-Jul;107(6-7):391-7. doi: 10.1016/j.acvd.2014.05.004. Epub 2014 Jun 26.

Supplemental Content

Loading ...
Support Center